A press release from CMS provides today’s answer:
[The Department of Health and Human Services] HHS hopes that each manufacturer will be committed to align American pricing for all brand products in all markets, which is currently not a general or biosimiller competition with the lowest price of a set of economic colleagues countries. The MFN target price is an OECD lowest price in the country with at least 60 percent of GDP per person per capita per capita per capita per capita.
Which countries will be included in the MFN comparison basket? Closing point report:
Under the most preferred nation mathematics, which will bind us the prices of medicine for those people Luxembourg, Ireland, Switzerland, Norway, Iceland, Denmark, Australia, Netherlands, Austria, Sweden, Belgium, Germany, Canada, Finland, Israel And this UK,
If HHS opposes using the per capita GDP by purchasing power equity as its metric, American prices may also be associated with them. Italy, Slovenia, New Zealand, Spain, The Czech Republic, South Korea, Lithuania and Japan,[my bolding]
Drugs with generic or biosimiller competition will be exempted from MFN talks.
